home / stock / alim / alim news

ALIM News and Press, Alimera Sciences Inc. From 08/09/22

Stock Information
Company Name: Alimera Sciences Inc.
Stock Symbol: ALIM
Market: NASDAQ
Website: alimerasciences.com
Menu
ALIM ALIM Quote ALIM Short ALIM News ALIM Articles ALIM Message Board
Get ALIM Alerts

News, Short Squeeze, Breakout and More Instantly...
ALIM - Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Portugal

Reimbursement granted with no restrictions to the label Alimera to begin selling later in Q3 ATLANTA, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to...
ALIM - Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q2 2022 Results - Earnings Call Transcript

Alimera Sciences, Inc. (ALIM) Q2 2022 Earnings Conference Call July 27, 2022 09:00 AM ET Company Participants Scott Gordon - CORE, Investor Relations Rick Eiswirth - President & Chief Executive Officer Phil Jones - Chief Financial Officer Conference Cal...

ALIM - Alimera Sciences Announces Second Quarter 2022 Financial Results

Consolidated Net Product Revenue of $14.6 Million up 36% vs. Second Quarter of 2021 U.S. End User Demand up 45% vs. Second Quarter of 2021 International Segment End User Demand Up 21% vs. Second Quarter of 2021 ATLANTA, July 27, 2022 (GLOBE NEWSWIRE...

ALIM - Alimera Sciences reports Q2 results

Alimera Sciences ( NASDAQ: ALIM ): Q2 For further details see: Alimera Sciences reports Q2 results

ALIM - Notable earnings before Wednesday's open

ADP , AEP , ALIM , ALKS , APH , ASC , ATOS , AVY , BA , OTCQX:BASFY , BG , BMY , BSX , BXMT , CAMT , CCJ , CHEF , CME , COOP , CPG , CS , CSTM , OTCQX:DANOY , DB , EDU , EQNR , EVR ...

ALIM - Paladin Phase 4 Study Confirms Safety of Durable ILUVIEN® Treatment and Reduces Burden of Care For DME Patients

ATLANTA, July 26, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced t...

ALIM - Alimera Sciences to Report Second Quarter 2022 Financial Results on Wednesday, July 27, 2022, and Provide Corporate Update

ATLANTA, July 22, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will...
ALIM - Alimera granted pricing, reimbursement in France for eye inflammation Iluvien injection

Alimera Sciences ( NASDAQ: ALIM ) on Friday said it would launch its Iluvien injection for the treatment of uveitis, a type of eye inflammation, in France through its distribution partner Horus Pharma. ALIM said Horus had been granted pricing and reimbursement approval...

ALIM - Alimera Announces Pricing and Reimbursement of Uveitis Indication Granted for ILUVIEN® in France

ATLANTA, July 22, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces th...

ALIM - Alimera Announces Data to Be Highlighted In Scientific Programming At Annual Congress

ATLANTA, July 13, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced t...
Previous 10 Next 10